28 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
-party payors and the medical community and our ability and our distribution and marketing partners’ ability to obtain coverage and adequate
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
product candidates among physicians, patients, patient advocacy groups, third-party payors and the medical community and our ability and our … acceptance of our product candidates among physicians, patients, patient advocacy groups, third-party payors and the medical community and our ability
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
acceptance of our product candidates among physicians, patients, patient advocacy groups, third-party payors and the medical community and our ability … relationships with suppliers, customers and others, (iv) the impact of the company’s operations on the community and the environment, (v
8-K
EX-99.2
dft8o2ct4hdpl
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
8qgx7
28 Feb 24
Annual report
7:33am
6-K
EX-99.4
tli998b1xm8x7v deu7o
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.3
gk0b 7tqnqfot6bjdu4
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.4
2rmf6j
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.3
taa6p9jg syjbf1pjez
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
j2bfu7srx
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
vm3z 3g4r6a3ojw2rqgc
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.4
8w7ln qe8
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
o8onbzpz51ne2untomn
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
424B7
54lz4
5 May 22
Prospectus with selling stockholder info
12:00am
F-3ASR
qa47f969u1gkz8gy
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
20-F
EX-2.4
lq1om1jwt w9odamkvq
25 Mar 21
Annual report (foreign)
7:01am
20-F
103fcrsfd355
25 Mar 21
Annual report (foreign)
7:01am